Huntsman Corporation (NYSE:HUN) is struggling to gain traction with investors, as evidenced by its 3.47 million shares volume. The daily trading volume average remained 2.52 million shares over the course of 3 months. The stock managed a 0.15% price change to reach $27.21 through the close.Huntsman Corporation (HUN) Analyst Opinion
Huntsman Corporation has a consensus outperform rating from 9 Wall Street analysts, and the number of shares currently sold short amount to at least 3.07% of shares outstanding. The stock sank -1.13% last month and is up 42.61 this year. Wall Street is only getting more bullish on the stock, with 9 of analysts who cover HUN having a buy-equivalent rating. Analysts have placed a $32.33 price target on Huntsman Corporation, suggesting a 18.82% gain from recent close. It’s currently trading about -5.09% below its 52-week high.
Huntsman Corporation (HUN) surprised the stock market in its last reported earnings when it earned $0.85 a piece versus the consensus-estimated $0.66. Its revenue totaled $2.62 billion up 6.3% from the previous quarter.Huntsman Corporation (NYSE:HUN) Intraday View
This stock (HUN) is ahead of its 52-week low with 76.98%. Its last month’s stock price volatility remained 1.54% which for the week stands at 1.73%. The share price has moved backward from its 20 days moving average, trading at a distance of -1.48% and stays 1.82% away from its 50 days moving average. Over the last five days, shares have faced -2.75% losses and now is up 12.09% since hitting its 200-day moving average of $25.75. Huntsman Corporation (HUN) has made its way to a 12-month gain of 62.54%.
Turning to FibroGen, Inc. (NASDAQ:FGEN), its shares were trading at $55.15 a gain of $0.05, on the trading floor. The stock, after opening at $55, touched a high of $55.15 before paring much of its gains. So far, analysts are sticking with their bullish recommendations with the consensus call at 1.6. FibroGen, Inc. has 5 buy ratings, 2 holds and 0 sells even after the stock tumbled -8.31% from its high of $60.15 to a $4.62 billion market value through last close.
The company’s consensus rating on Reuter’s scale improved from 1.33 to 1.57 during a month. Analysts set a 12-month price target of $68 a share. The target implies a 23.3% spike from where the shares are currently trading. Also, the current price highlights a discount of 48.69% to analysts’ high consensus price target.FibroGen, Inc. (NASDAQ:FGEN) Intraday Trading
The counter witnessed a trading volume of 0.55 million shares versus an average volume of 0.92 million shares during last trading session. Its last month’s stock price volatility remained 4.2% which for the week approaches 3.57%. The lowest price the stock reached in the last trading day was $53.87 and compares with the $15.6 52-week low. The stock recovered 253.53% since its low point and has performed 157.71% year-to-date.